Iodixanol: Risk of subsequent contrast nephropathy in cancer patients with underlying renal insufficiency undergoing diagnostic computed tomography examinations

Journal of Computer Assisted Tomography

Volumn 31, Issue 4, 2007, Pages 493-498

  Cheruvu, Bharadwaj ^a   Henning, Kathleen ^a   Mulligan, Janine ^a   Klippenstein, Donald ^a   Lawrence, David ^a   Gurtoo, Lalit ^a   Gottlieb, Ronald H ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Computed tomography; Contrast induced nephropathy

Indexed keywords

BODY FLUIDS; COMPUTERIZED TOMOGRAPHY; CREATININE; DIAGNOSIS; DISEASES;

CANCER PATIENTS; COMPUTED TOMOGRAPHY; CONTRAST AGENT; CONTRAST-INDUCED NEPHROPATHY; INSTITUTIONAL REVIEW BOARDS; INTRAVENOUS CONTRAST; IOHEXOL; NEPHROPATHY; RENAL FUNCTIONS; RETROSPECTIVE EVALUATIONS;

RISK ASSESSMENT;

CREATININE; IODIXANOL; IOHEXOL;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PATIENT; CHILD; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIAGNOSTIC PROCEDURE; FEMALE; HUMAN; INCIDENCE; INFORMED CONSENT; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY INJURY; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEX DIFFERENCE; TREATMENT CONTRAINDICATION;

EID: 34648822072     PISSN: 03638715     EISSN: None     Source Type: Journal    
DOI: 10.1097/rct.0b013e31802e29d9     Document Type: Article

References (36)

1. Gleeson TG, Bulugahapitiya S. Contrast induced nephropathy. AJR Am J Roentgenol. 2004;183:1673-1689. (Review).
2. Solomon R, Werner C, Mann D, et al. Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents. N Engl J Med. 1994;331:1416-1420.
3. Tepel M, Zidek W. Acetylcysteine and contrast media nephropathy. Curr Opin Nephrol Hypertens. 2002;11:503-506.
4. Tepel M, Van der Giet M, Schwarzfeld C, et al. Prevention of radiographic-contrast agent induced reductions in renal function by acetylcysteine. N Engl J Med. 2000;343:180-184.
5. Huber W, Ilgmann K, Page M, et al. Effect of theophylline on contrast material induced nephropathy in patients with chronic renal insufficiency: controlled, randomized double-blinded study. Radiology. 2002;223:772-779.
6. Merten G, Burgess W, Gray L, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA. 2004;291:2328-2334.
7. Goldenberg I, Matetzky S. Nephropathy induced by contrast media: pathogenesis, risk factors, and preventive strategies. CMAJ. 2005;172:1461-1471.
8. Becker C, Reiser MF. Use of iso-osmolar nonionic dimeric contrast media in multidetector row computed tomography angiography for patients with renal impairment. Invest Radiol. 2005;40:672-675.
9. Carraro M, Malalan F, Antonione R, et al. Effects of a dimeric vs a monomeric nonionic contrast medium on renal function in patients with mild to moderate renal insufficiency: a double-blind, randomized clinical trial. Eur Radiol. 1998;8:144-147.
10. Chalmers N, Jackson RW. Comparison of iodixanol and iohexol in renal impairment. Br J Radiol. 1999;72:701-703.
11. Mehran R, Nikolsky E. Contrast-induced nephropathy: definition, epidemiology, and patients at risk. Kidney Int Suppl. 2006;100:S11-S15.
12. Schrader R. Contrast material-induced renal failure: an overview. J Interv Cardiol. 2005;18:417-423.
13. Cox CD, Tsikouis JP. Preventing contrast nephropathy: what is the best strategy? A review of the literature. J Clin Pharmacol. 2004;44:327-337.
14. Pannu N, Wiebe N, Tonelli M. Prophylaxis strategies for contrast-induced nephropathy. JAMA. 2006;295:2765-2779.
15. Narang R, Sakhare M, Bahl VS. Contrast induced nephropathy. Indian Heart J. 2004;56:13-20.
16. Barrett BJ, Parfrey PS, Vavasour HM, et al. Contrast nephropathy in patients with impaired renal function: high vs low osmolar media. Kidney Int. 1992;41:1274-1279.
17. Rudnick MR, Goldfarb S, Wexler L, et al. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The iohexol cooperative study. Kidney Int. 1995;47:254-261.
18. Thomsen HS, Morcos SK. Contrast media and the kidney: European Society of Urogenital Radiology (ESUR) guidelines. Br J Radiol. 2003;76:513-519.
19. Aspelin P, Aubry P, Fransson S, et al. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med. 2003;348:491-499.
20. Bakris GL, Lass N, Gaber AO, et al. Radiocontrast medium-induced declines in renal function: a role of oxygen free radicals. Am J Physiol. 1990;258:F115-F120.
21. Parvez Z, Rahman MA, Moncada R. Contrast media-induced lipid peroxidation in the rat kidney. Invest Radiol. 1989;24:697-702.
22. Rao QA, Newhouse J. Risk of nephropathy after intravenous administration of contrast material: a critical literature analysis. Radiology. 2006;239:392-397.
23. Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation. 2002;105:2259-2264.
24. Freeman RV, O'Donnell M, Share D, et al. Nephropathy requiring dialysis after percutaneous coronary intervention and the critical role of an adjusted contrast dose. Am J Cardiol. 2002;90:1068-1073.
25. Ashby DT, Mehran R, Aymong EA, et al. Comparison of outcomes in men versus women having percutaneous coronary interventions in small coronary arteries. Am J Cardiol. 2003;91:979-981.
26. Cochran ST, Wong WS, Roe DJ. Predicting angiography-induced acute renal function impairment: clinical risk model. AJR Am J Roentgenol. 1983;141:1027-1033.
27. Bartholomew BA, Harjai KJ, Dukkipati S, et al. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol. 2004;93:1515-1519.
28. Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004;44:1393-1399.
29. Taliercio CP, Vliestra RE, Fisher LD, et al. Risks for renal dysfunction with cardiac angiography. Ann Intern Med. 1986;104:501-504.
30. McCullough PA, Wolyn R, Rocher LL, et al. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med. 1997;103:368-375.
31. Polena S, Yang S, Alam R, et al. Nephropathy in critically ill patients without preexisting renal disease. Proc West Pharmacol Soc. 2005;48:134-135.
32. Parfrey PS, Griffiths SM, Barrett BJ, et al. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. N Engl J Med. 1989;320:143-149.
33. Verhave JC, Fesier P, Ribstein J, et al. Estimation of renal function in subjects with normal serum creatinine levels: influence of age and body mass index. Am J Kidney Dis. 2005;46:233-241.
34. Petrik M, Weigel C, Kirsch M, et al. No detectable nephrotoxic side effect using a dimer, non-ionic contrast media in cerebral perfusion computed tomography in case of suspected brain ischemia. Rofo. 2005;177:1242-1249.
35. Liss P, Persson PB, Hansell P, et al. Renal failure in 57,925 patients undergoing coronary procedures using iso-osmolar or low-osmolar contrast media. Kidney Int. 2006;70:1811-1817.
36. Jo SH, Youn TJ, Koo BK, et al. Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled trial. J Am Coll Cardiol. 2006;48:924-930.